Japan records surprise trade deficit in July as exports weaken further
BURLINGTON, MA – Fractyl Health , Inc. (NASDAQ:GUTS), a medical device company specializing in surgical and medical instruments with a current market capitalization of $66 million, announced today that its Board of Directors has established June 11, 2025, as the date for the company’s 2025 annual meeting of stockholders. This announcement comes as the company’s stock trades near its 52-week low, having declined over 80% in the past year. According to InvestingPro analysis, which offers comprehensive insights through its Pro Research Reports covering 1,400+ US stocks, the company faces significant challenges with cash burn and profitability. This announcement follows the omission of an annual meeting in 2024.
The company, which is incorporated in Delaware and headquartered in Burlington (NYSE:BURL), Massachusetts, stated that further details about the meeting’s time, location, and agenda will be included in the proxy statement for the 2025 annual meeting. InvestingPro data shows the company maintains a current ratio of 3.63, indicating sufficient liquid assets to meet short-term obligations despite challenging market conditions.
Fractyl Health also outlined guidelines for stockholder proposals. To be considered for inclusion in the proxy materials, stockholder proposals must be received by the Corporate Secretary at the company’s principal executive offices by March 23, 2025. This deadline is set to allow sufficient time for the company to print and distribute proxy materials. Proposals must also comply with the rules and regulations of the Securities and Exchange Commission (SEC).
In addition, stockholders intending to bring business before the annual meeting or nominate a director must provide notice by the same March 23 deadline. Notices must adhere to the specific requirements outlined in the company’s Amended and Restated Bylaws and Rule 14a-19 under the Exchange Act.
The information regarding the 2025 annual meeting and the process for stockholder nominations and proposals is based on a recent SEC filing by Fractyl Health. The company’s decision to hold the annual meeting comes as part of its compliance with corporate governance norms and the SEC’s regulations. With an overall Financial Health Score rated as ’WEAK’ by InvestingPro, which offers 12 additional exclusive insights about the company, stakeholders will likely focus on strategic initiatives to improve financial performance at the upcoming meeting.
In other recent news, Fractyl Health Inc. reported its Q4 2024 earnings, revealing a significant earnings miss with an EPS of -$0.52, compared to the analyst forecast of -$0.42. The company experienced a net loss of $25 million, driven by increased R&D expenses, which rose to $20.3 million from $10.1 million in the previous year. Revenue was generated from a commercial pilot in Germany, though specific figures were not disclosed. Fractyl Health’s focus remains on its RAVITA and REJUVA platforms, which are expected to achieve key milestones in 2025, including open-label data from the REVEAL-ONE study and a midpoint analysis of the REMAIN-ONE study. Despite the earnings miss, the company maintains a cash position of $67.5 million, which is anticipated to support operations into 2026. Fractyl Health is also preparing for a CTA submission for its REJUVA001 gene therapy in the first half of 2025. The company has not announced any upgrades or downgrades from analyst firms, but the market remains skeptical, as reflected in the stock’s performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.